Clinical Trial Update: Faslodex Registry: Fulvestrant in Current Clinical Practice

View source ↗

Summary

AstraZeneca's Faslodex Registry study evaluating fulvestrant in current clinical practice for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Breast Cancer | Status: COMPLETED